Abstract
Poor differentiation is an important hallmark of cancer cells, and differentiation therapy holds great promise for cancer treatment. The restoration of IkB kinase α (IKKα) leads to the differentiation of nasopharyngeal carcinoma cells with reduced tumorigenicity. The findings by Yan et al. validate the polycomb protein enhancer of zeste homologue 2 (EZH2) as a target for intervention.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Carcinoma
-
Cell Differentiation / drug effects
-
Enhancer of Zeste Homolog 2 Protein / metabolism*
-
Epigenesis, Genetic / drug effects
-
Humans
-
I-kappa B Kinase / genetics*
-
I-kappa B Kinase / metabolism
-
Molecular Targeted Therapy
-
Nasopharyngeal Carcinoma
-
Nasopharyngeal Neoplasms / drug therapy*
-
Nasopharyngeal Neoplasms / genetics
-
Nasopharyngeal Neoplasms / metabolism
Substances
-
Antineoplastic Agents
-
EZH2 protein, human
-
Enhancer of Zeste Homolog 2 Protein
-
CHUK protein, human
-
I-kappa B Kinase